Article

You have full text access to this OnlineOpen article

Stage I-II follicular lymphoma: Treatment results for 76 patients

  1. Peter McLaughlin MD1,*,
  2. Lillian M. Fuller MD2,
  3. William S. Velasquez MD1,
  4. Jane A. Sullivan-Halley BS1,
  5. James J. Butler MD3,
  6. Fernando Cabanillas MD1

Article first published online: 28 JUN 2006

DOI: 10.1002/1097-0142(19861015)58:8<1596::AID-CNCR2820580803>3.0.CO;2-G

Issue

Cancer

Cancer

Volume 58, Issue 8, pages 1596–1602, 15 October 1986

Additional Information

How to Cite

McLaughlin, P., Fuller, L. M., Velasquez, W. S., Sullivan-Halley, J. A., Butler, J. J. and Cabanillas, F. (1986), Stage I-II follicular lymphoma: Treatment results for 76 patients. Cancer, 58: 1596–1602. doi: 10.1002/1097-0142(19861015)58:8<1596::AID-CNCR2820580803>3.0.CO;2-G

Author Information

  1. 1

    Departments of Hematology, The University of Texas M. D. Anderson Hospital and Tumor Institute, Houston, Texas

  2. 2

    Departments of Radiotherapy, The University of Texas M. D. Anderson Hospital and Tumor Institute, Houston, Texas

  3. 3

    Departments of Pathology, The University of Texas M. D. Anderson Hospital and Tumor Institute, Houston, Texas

*UTMD Anderson Hospital, 6723 Bertner Avenue, Houston, TX 77030

Publication History

  1. Issue published online: 28 JUN 2006
  2. Article first published online: 28 JUN 2006
  3. Manuscript Accepted: 10 FEB 1986

Funded by

  • US Public Health Service. Grant Numbers: CA 06294, CA 16672

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

Get PDF (627K)

Abstract

Clinical features and treatment results are analyzed for 76 patients with Stage I-II follicular lymphoma seen between 1974 and 1981. During this period, 66% of the patients received involved-field radiotherapy (XRT) alone, and 34% received chemotherapy with or without XRT. At 5 years, the overall survival was 67%, the cause-specific survival was 73%, and the relapse-free survival (RFS) was 48%, with no relapses to date among nine patients followed beyond 60 months. Adverse prognostic features for survival included extranodal disease and elevated serum lactate dehydrogenase. For RFS, adverse features included extranodal disease and bulky abdominal disease. The RFS was significantly better for patients receiving chemotherapy with or without XRT than for XRT alone (64% versus 37% at 5 years, P = 0.02), despite a higher frequency of adverse prognostic features in the chemotherapy-treated group. About 50% of Stage I-II follicular lymphoma patients may be curable, and the inclusion of chemotherapy in the initial treatment may increase the potentially curable fraction.

Get PDF (627K)